Latest Breaking News On - Great point partners - Page 4 : comparemela.com

Neurogene (NASDAQ:NGNE) Now Covered by Analysts at SVB Leerink

SVB Leerink started coverage on shares of Neurogene (NASDAQ:NGNE – Free Report) in a research note published on Monday, Marketbeat reports. The firm issued an outperform rating and a $46.00 price target on the stock. NGNE has been the subject of a number of other research reports. William Blair began coverage on Neurogene in a […]

William blairStifel nicolausPrivium fund management united kingdom ltdGreat point partnersCapital managementNeurogene incFree reportFund management united kingdom ltdPartners managementGet free reportNeurogene dailyNasdaq ngneInitiated coverageSvb leerink llc

Alumnus donates funding for Saint John s to launch finance program

Alumnus donates funding for Saint John s to launch finance program
wbjournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wbjournal.com Daily Mail and Mail on Sunday newspapers.

United statesJoe dohertyJeffreyr jayJeffrey jaySaint john high schoolSaint john high school of shrewsburySaint johnHigh schoolGreat point partnersFinance programJay chair

Neurogene (NASDAQ:NGNE) Earns Outperform Rating from Leerink Partnrs

Leerink Partnrs reaffirmed their outperform rating on shares of Neurogene (NASDAQ:NGNE – Free Report) in a report issued on Monday morning, Zacks.com reports. Leerink Partnrs also issued estimates for Neurogene’s Q1 2024 earnings at ($1.19) EPS. Other research analysts have also issued research reports about the stock. SVB Leerink started coverage on shares of Neurogene […]

Leerink partnrsStifel nicolausWilliam blairGreat point partnersCapital managementNeurogene incPrivium fund management united kingdom ltdFree reportFund management united kingdom ltdPartners managementGet free reportNeurogene dailyNasdaq ngneReiterated rating

Brokerages Set Terns Pharmaceuticals, Inc (NASDAQ:TERN) Target Price at $14 94

Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the eight research firms that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The […]

Institutional investors weigh in on terns pharmaceuticalsNews ratings for terns pharmaceuticals dailyDecheng capitalInsider activity at terns pharmaceuticalsTerns pharmaceuticals stock performanceRussell investments group ltdAffinity asset advisorsAnalyst recommendations for terns pharmaceuticalsSecurities exchange commissionVivo opportunity llcGreat point partnersTerns pharmaceuticals incTerns pharmaceuticalsGet free reportMarketbeat ratingsVivo opportunity

Context Therapeutics Announces $100 Million Private Placement

Financing includes new and existing leading healthcare investors

United statesGina mangiaracinaPiper sandlerJennifer minai azaryExchange commissionGreat point partnersNextech invest ltdCompany nasdaqContext therapeutics incAlly bridge groupAvidity partnersBlackstone multi asset investingBlue owl healthcare opportunitiesDeep track capitalDriehaus capital managementSecurities act